SUPERNUS PHARMACEUTICALS, INC.SUPN

SUPERNUS PHARMACEUTICALS, INC. Segments Disclosure

10-KFiled Feb 25, 20252 min read
Segment Reporting
The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.

The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, and decides how to allocate resources based on net income, which is reported in the consolidated statement of earnings as net earnings and allocates resources on a consolidated basis. The CODM uses net earnings to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings is also used to monitor budget versus actual results.

The measure of the reportable segment assets is reported on the balance sheet as total assets.

The accounting policies of the reportable segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):
Year Ended December 31,
202420232022
Total revenues
$661,817 $607,521 $667,238 
Less: Significant Segment Expenses:
Cost of goods sold
77,906 83,779 87,221 
Selling153,105 149,955 147,289 
Marketing74,188 79,231 120,499 
General and administrative94,289 107,175 109,433 
Research and development expenses


External development program expenses:
ONAPGO
1,641 3,825 1,942 
SPN-82027,042 12,311 8,139 
SPN-8179,837 9,397 7,341 
Qelbree15,819 11,101 8,641 
Early-stage programs and other expenses
16,352 20,467 16,929 
Total external development program expenses
70,691 57,101 42,992 
Internal employee-related expenses
38,105 34,492 31,560 
Total research and development expenses
108,796 91,593 74,552 
Other segment items(a)
79,668 94,472 67,533 
Net earnings
$73,865 $1,316 $60,711 

(a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the consolidated statement of earnings.
Free Sentinel

Want the next SUPERNUS PHARMACEUTICALS, INC. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment SUPERNUS PHARMACEUTICALS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesCommitmentsStock CompensationNew Standards